Menu

GM Study Declared Unsound

A controversial study that suggested genetically modified (GM) maize causes cancer in rats is dismissed by the European Food Safety Authority.

Nov 29, 2012
Jef Akst

Wikimedia, Sreejith KA task force set up by the European Food Safety Authority (EFSA) yesterday (November 28) has confirmed suspicions that a September study claiming to have identified serious health consequences of genetically modified (GM) maize “does not meet acceptable scientific standards.”

The 2-year-long study examined rats fed a Europe- and United States-approved GM corn, called NK603, and claimed they developed massive mammary tumors and died earlier than rats fed conventional corn. The results, which were published in September in Food and Chemical Toxicology, were met with immediate skepticism, leading to an independent evaluation by two French regulatory agencies and the EFSA. Last month (October 4), the EFSA announced its preliminary conclusion that “the design, reporting and analysis of the study, as outlined in the paper, are inadequate.” Now, the agency has declared with more certainty that the study “does not meet acceptable scientific standards, and there is no need to re-examine previous safety evaluations of genetically modified maize NK603.”

The European Union uses millions of tons of GM crops, including NK603 corn, as livestock feed.

(Hat tip to ScienceInsider)

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.